Start-up CalTIC secures up to EUR 3 million in seed financing to develop a new class of drugs targeting TRPC channels
Promising new approach for the treatment of widespread conditions, including metabolic diseases, obesity, and heart hypertrophy
29-Sep-2022 -
The KHAN Technology Transfer Fund I (KHAN-I) has committed up to EUR 3 million in milestone-dependent payments to CalTIC, a Dortmund based start-up, for the discovery of a new class of drugs.
The start-up builds on a long-term collaboration between the Lead Discovery Center GmbH (LDC), the Max ...
cardiac hypertrophy
cardiovascular diseases
drug discovery
+4